Skip to content

Cumberland Pharmaceuticals CPIX Other investment liability

Other investment liability at other companies

Financial Institutions logo
Financial InstitutionsFISI
$29.62M-55.2%
Beneficient logo
BeneficientBENF
$1.16M+12.7%
Republic Bancorp logo
Republic BancorpRBCAA
$131.44M-5.5%
SolarEdge Technologies logo
SolarEdge TechnologiesSEDG
$631K-46.8%
Dave & Buster's Entertainment logo
Dave & Buster's EntertainmentPLAY
$1.3M+208%
V2X logo
V2XVVX
$7.69M-49.6%

Other financials

Income statement

See full
Revenue$9.1M-22.0%
Gross profit$7.2M-30.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Cash & equivalents$11.0M-27.1%
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation

See full
Market cap$97.09M+138%
Enterprise value$90.91M+207%
P/S2.3×+1.3×

Profitability

See full
Gross margin82.9%-1.4pp
Operating margin-17.2%-125pp
Net margin-17.6%-103pp
FCF margin3.3%

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×
Current ratio-0.3×

Where this comes from

Reported directly by Cumberland Pharmaceuticals in its filing.

Tagged under the XBRL concept cpix:OtherInvestmentLiability.

The official record: Cumberland Pharmaceuticals’s 10-K, filed March 9, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's other investment liability.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cumberland Pharmaceuticals's other investment liability?
Cumberland Pharmaceuticals (CPIX) reported other investment liability of $500K in Q4 2025.
What does other investment liability mean?
This metric captures financial obligations arising from investment-related activities that do not fall under standard debt or accounts payable categories. It typically represents contingent liabilities or deferred payments associated with strategic acquisitions or partnership agreements. Tracking this liability is essential for assessing the company's total potential financial exposure beyond its primary operating debt.